Seikagaku will announce the financial results for the Fiscal Year ended March, 31 2018 at 16:00 on May 11, 2018.
Seikagaku Announces Revision of Consolidated Financial Forecasts for the Fiscal 2017 ending March 2018
Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation.
Seikagaku Initiates a Phase III Clinical Trial (Additional Study) in the U.S. for SI-6603, Indicated for Treatment of Lumbar Disc Herniation
Consolidated Financial Results for the Thrid Quarter of Fiscal year 2017